24 November 2008

Sodium oxybate

is GHB. It's currently being used for excessive daytime sleepiness and cataplexy. Now, it may be approved for fibromyalgia, according to DIA:

Sodium oxybate may reduce pain in patients with fibromyalgia, study suggests.

Bloomberg News (11/21, Pollack) reports, "Jazz Pharmaceuticals Inc. and UCB SA said their treatment for fibromyalgia," sodium oxybate "reduced patients' pain and fatigue in an advanced study." In the study of 548 patients," researchers found that "sodium oxybate, helped patients achieve a 30 percent reduction in pain compared with a placebo." Jazz will "ask by the end of 2009 that the U.S. Food and Drug Administration clear the therapy for sale. UCB anticipates requesting European Union clearance later."

Brad Evans